Montana Experimental Treatment Review Board
An independent board of accredited physicians, scientists, and ethicists that evaluates experimental treatments through structured review of safety, monitoring, and informed consent under Montana Senate Bill 535.
Authority & Legal Basis
under Montana's
Senate Bill 535
The Montana Experimental Treatment Review Board operates under Montana Senate Bill 535, enacted in 2025.
The board provides independent review of experimental treatment proposals, evaluating safety considerations, patient monitoring plans, informed consent procedures, and treatment eligibility criteria within the scope established by Montana law.
The board's role is to provide structured review and recommendations through a multidisciplinary panel of physicians, scientists, and ethicists.
The Review Board

Matt Kaeberlein
Biologist and aging researcher, University of Washington
Matt Kaeberlein, PhD, is a biologist focused on the biology of aging and translational longevity science. He is co-founder of the Dog Aging Project and founding director of the University of Washington Healthy Aging and Longevity Research Institute.

Jessica
Flanigan
Bioethicist and author, University of Richmond
Jessica Flanigan is the Richard L. Morrill Chair in Ethics and Democratic Values at the University of Richmond. Her work focuses on medical ethics, patient autonomy, and public policy.

Jamie
Justice
Translational geroscientist, XPRIZE Healthspan
Jamie Justice, PhD, is Executive Vice President of Health at XPRIZE and Executive Director of the XPRIZE Healthspan Prize. Her research focuses on aging biology, clinical trials, and gerotherapeutic interventions.

Danielle Ruiz
Montana-licensed physician
Danielle Ruiz, MD, is a Montana-licensed physician participating in the board’s clinical review and patient safety oversight activities.

What the Board Reviews
The board evaluates experimental treatment proposals through review of safety, monitoring, informed consent, and patient eligibility frameworks.
Safety Information
Assessment of available safety data, known risks, and supporting evidence relevant to the proposed treatment.
Monitoring Plans
Review of patient monitoring procedures, adverse event reporting, and follow-up protocols.
Informed Consent
Evaluation of informed consent materials to ensure patients receive clear and accurate information regarding potential risks and benefits.
Eligibility Criteria
Review of patient inclusion and exclusion criteria and the rationale supporting treatment eligibility.

How Review Works
The applicant provides treatment information, supporting documentation, safety materials, monitoring plans, informed consent documents, and eligibility criteria.
Board members evaluate submitted materials and assess the proposal against the review criteria established under the board's framework.
The board issues its review outcome and recommendations based on the information provided and the review conducted.
Review requirements and discuss whether your proposal is appropriate for board review.
Frequently Asked Question
Our Expertise Across Various Economic Sectors

Technology
.avif)
Healthcare

Financial Services

Manufacturing

Retail

Energy

Real Estate
.avif)



.avif)
.avif)